YMRC
GRDN

Yorktown Management & Research Company’s Guardian Pharmacy Services GRDN Stock Holding History

Yorktown Management & Research Company’s Portfolio GRDN Stock Details GRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
+7,850
New +$304K 0.2% 194

Other funds holding GRDN

RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
KPP
Kings Path Partners Sugar Land, Texas $376M AUM 19% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return

Yorktown Management & Research Company's GRDN Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Guardian Pharmacy Services (GRDN) in Q2 2026: 7,850 shares worth $329K. The stake represents 0.2% of the portfolio and ranks #194 among its holdings.

22 funds tracked by Wall St. Rank hold GRDN as of Q2 2026.

  • Yorktown Management & Research Company held 7,850 shares of Guardian Pharmacy Services worth $329K as of Q2 2026.
  • Guardian Pharmacy Services was a new Yorktown Management & Research Company position in Q2 2026.
  • Guardian Pharmacy Services made up 0.2% of Yorktown Management & Research Company's portfolio in Q2 2026, its #194 holding.
  • 22 funds tracked by Wall St. Rank held Guardian Pharmacy Services as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.